AI Engines For more Details: Perplexity Kagi Labs You
Gastrointestinal Health: Enterococcus faecium SF68 has been shown to promote gastrointestinal health by restoring the balance of gut microbiota. It can help alleviate symptoms of diarrhea, including infectious diarrhea, antibiotic-associated diarrhea, and traveler's diarrhea. Additionally, it may help improve symptoms of irritable bowel syndrome (IBS) by reducing abdominal discomfort and irregular bowel movements.
Immune Function: Probiotics like Enterococcus faecium SF68 interact with the immune system, stimulating the production of certain immune factors and enhancing the activity of immune cells. This modulation of the immune response may help strengthen the body's defenses against infections and reduce the risk of respiratory tract infections, urinary tract infections, and other infectious diseases.
Vaginal Health: Some research suggests that Enterococcus faecium SF68 may play a role in maintaining vaginal health by promoting a balanced vaginal microbiota. It can help prevent the overgrowth of harmful bacteria and yeast in the vaginal tract, reducing the risk of vaginal infections such as bacterial vaginosis and yeast infections.
Antimicrobial Properties: Enterococcus faecium SF68 produces antimicrobial substances that inhibit the growth of pathogenic bacteria, thereby contributing to the protection of the host against infections. It may help reduce the colonization of harmful bacteria in the gastrointestinal tract and other mucosal surfaces.
Antioxidant Activity: Some studies have suggested that Enterococcus faecium SF68 may exhibit antioxidant properties, which can help reduce oxidative stress and inflammation in the body. This antioxidant activity may have beneficial effects on overall health and may help protect against chronic diseases such as cardiovascular disease and cancer.
Nutrient Absorption: Enterococcus faecium SF68 may enhance nutrient absorption in the intestine by improving the integrity of the intestinal barrier and promoting the digestion and absorption of dietary nutrients. This can contribute to overall health and well-being by ensuring adequate nutrient uptake from food.
Skin Health: There is some evidence to suggest that probiotics like Enterococcus faecium SF68 may have beneficial effects on skin health by modulating the immune response and reducing inflammation. It may help alleviate symptoms of certain skin conditions such as eczema, acne, and atopic dermatitis.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Enterococcus durans | Increases |
| species | Enterococcus faecalis | Increases |
| species | Enterococcus faecium | Increases |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.6 | 0.17 |
| Allergies | 1.3 | 0.5 | 1.6 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alzheimer's disease | 1.2 | 0.6 | 1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.7 | 0.86 |
| Ankylosing spondylitis | 1.5 | 0.8 | 0.88 |
| Anorexia Nervosa | 0.5 | 0.3 | 0.67 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.5 | 0.5 | 0 |
| Atrial fibrillation | 1 | 1.6 | -0.6 |
| Autism | 2.5 | 1.5 | 0.67 |
| benign prostatic hyperplasia | 0.7 | 0.7 | |
| Bipolar Disorder | 2.1 | 2.1 | |
| Brain Trauma | 1 | 1 | |
| Carcinoma | 0.7 | 0.7 | |
| Celiac Disease | 0.7 | 0.5 | 0.4 |
| Cerebral Palsy | 0.6 | -0.6 | |
| Chronic Fatigue Syndrome | 1 | 0.6 | 0.67 |
| Chronic Kidney Disease | 0.7 | 0.7 | |
| Chronic Lyme | 0.5 | 0.5 | |
| Chronic Urticaria (Hives) | 0.9 | 0.3 | 2 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.5 | |
| Colorectal Cancer | 1.7 | 1.7 | |
| Constipation | 1.6 | 1.6 | |
| COVID-19 | 2.3 | 2 | 0.15 |
| Crohn's Disease | 1.9 | 1.3 | 0.46 |
| cystic fibrosis | 1 | 0.6 | 0.67 |
| deep vein thrombosis | 1.5 | 1.5 | |
| Depression | 1.5 | 1.6 | -0.07 |
| Eczema | 1.2 | 0.6 | 1 |
| Endometriosis | 1.3 | 1.3 | |
| Epilepsy | 0.8 | 0.6 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 1.8 | 1.8 | |
| gallstone disease (gsd) | 0.7 | 0.7 | |
| Generalized anxiety disorder | 0.8 | 0.8 | 0 |
| Graves' disease | 0.5 | -0.5 | |
| Hashimoto's thyroiditis | 0.2 | -0.2 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.8 | -0.6 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.8 | |
| hyperglycemia | 0.7 | 0.7 | |
| hypersomnia | 0.2 | 0.2 | |
| hypertension (High Blood Pressure | 1.5 | 0.4 | 2.75 |
| IgA nephropathy (IgAN) | 1.1 | 1.1 | |
| Inflammatory Bowel Disease | 1.2 | 1 | 0.2 |
| Irritable Bowel Syndrome | 2.3 | 1 | 1.3 |
| Liver Cirrhosis | 2.1 | 0.6 | 2.5 |
| Long COVID | 2.1 | 2 | 0.05 |
| Lung Cancer | 0.7 | 0.7 | |
| ME/CFS with IBS | 0.6 | 0.6 | 0 |
| ME/CFS without IBS | 0.6 | 0.6 | 0 |
| Metabolic Syndrome | 2.3 | 0.8 | 1.87 |
| Mood Disorders | 2.7 | 2.1 | 0.29 |
| myasthenia gravis | 0.5 | -0.5 | |
| Neuropathy (all types) | 0.5 | -0.5 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.2 | 0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.3 | 1.3 | |
| Obesity | 1.5 | 1.5 | |
| obsessive-compulsive disorder | 1.5 | 0.6 | 1.5 |
| Osteoarthritis | 0.5 | 0.5 | |
| Osteoporosis | 0.7 | 0.7 | |
| Parkinson's Disease | 0.9 | 1.4 | -0.56 |
| Polycystic ovary syndrome | 1.2 | 1.2 | |
| Postural orthostatic tachycardia syndrome | 0.5 | 0.5 | |
| Psoriasis | 0.2 | 0.6 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.9 | 1.1 | 1.64 |
| Rosacea | 0.2 | -0.2 | |
| Schizophrenia | 1.4 | 0.7 | 1 |
| Sjögren syndrome | 0.7 | 0.7 | |
| Sleep Apnea | 0.7 | 0.7 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 1 | 0.2 |
| Stress / posttraumatic stress disorder | 0.8 | 0.6 | 0.33 |
| Systemic Lupus Erythematosus | 1.6 | 1.5 | 0.07 |
| Type 1 Diabetes | 0.5 | 0.5 | |
| Type 2 Diabetes | 1.5 | 0.8 | 0.88 |
| Ulcerative colitis | 3.1 | 1.8 | 0.72 |
| Unhealthy Ageing | 0.5 | 0.6 | -0.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.